文献速递眼底病与葡萄膜炎

通过持续递送血管内皮生长因子受体酪氨酸激酶抑制剂治疗视网膜/脉络膜血管疾病

Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.
PubMed 文献 · Am J Ophthalmol · 2025-06-10

本文为叙述性综述,评估通过玻璃体内水凝胶植入、脉络膜上腔注射、皮下递送及口服等持续释放平台递送VEGF受体酪氨酸激酶抑制剂(TKI)的临床前与临床研究。阿昔替尼、舒尼替尼、沃罗拉尼、登德拉尼等TKI在新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿和糖尿病视网膜病变的早期研究中显示一定治疗持久性、减少抗VEGF注射负担并维持解剖和功能结局,安全性总体良好但部分制剂有剂量依赖性不良反应。作者认为该策略是有前景的治疗范式,需更大规模对照临床试验验证。

要点

  • 多种VEGF受体TKI通过植入、脉络膜上腔注射、微粒悬浮或口服/皮下平台持续递送,早期研究显示可减少抗VEGF注射负担。
  • 部分制剂出现剂量依赖性不良反应,安全性总体良好但各制剂差异需关注。
  • 作者认为需通过更大规模对照临床试验验证早期发现并明确这些药物的临床角色。

核心结论

  • 持续递送VEGF受体TKI是视网膜和脉络膜血管疾病的有前景治疗范式,可能减少治疗负担并维持疗效。
  • 作者认为需通过更大规模对照临床试验验证这些早期发现并明确这些药物在临床实践中的角色。

研究设计与样本

  • 叙述性综述,综合评估经持续释放平台递送VEGF受体TKI的临床前和临床研究的安全、疗效与持久性。
  • 持续释放平台包括玻璃体内水凝胶植入、脉络膜上腔注射、皮下递送系统和口服制剂。

主要发现

  • 阿昔替尼、舒尼替尼、沃罗拉尼和登德拉尼等多种VEGF受体TKI正在接受新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿和糖尿病视网膜病变的持续治疗评估。
  • 生物可蚀性植入物(OTX-TKI/阿昔替尼、EYP-1901/沃罗拉尼)、脉络膜上腔注射(CLS-AX/阿昔替尼)、微粒悬浮液(GB-102/舒尼替尼)及口服或皮下治疗(X-82、D-4517.2)在早期研究中显示不同程度的治疗持久性、抗VEGF注射负担减少及解剖和功能结局维持。
  • 安全性总体良好,但某些制剂显示剂量依赖性不良反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需通过更大规模对照临床试验验证这些早期发现并明确这些药物的临床角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review current investigational strategies using sustained delivery of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs) for the treatment of retinal and choroidal vascular diseases. DESIGN: Narrative review. METHODS: A comprehensive review of preclinical and clinical studies evaluating the safety, efficacy, and durability of VEGF receptor TKIs delivered via sustained-release platforms, including intravitreal hydrogel implants, suprachoroidal injections, subcutaneous delivery systems, and oral formulations. RESULTS: Multiple VEGF receptor TKIs, including axitinib, sunitinib, vorolanib, and dendranib, are under evaluation for sustained treatment of neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Delivery platforms such as bioerodible implants (OTX-TKI/axitinib, EYP-1901/vorolanib), suprachoroidal injections (CLS-AX/axitinib), microparticle suspensions (GB-102/sunitinib), and oral or subcutaneous therapies (X-82, D-4517.2) have demonstrated variable degrees of treatment durability, reduction in anti-VEGF injection burden, and maintenance of anatomic and functional outcomes in early phase studies. Safety profiles have generally been favorable, although certain formulations showed dose-dependent adverse effects. CONCLUSIONS: Sustained delivery of VEGF receptor TKIs represents a promising therapeutic paradigm for retinal and choroidal vascular diseases, potentially reducing treatment burden while maintaining efficacy. Continued evaluation through larger, controlled clinical trials is essential to validate these early findings and define the role of these agents in clinical practice.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Dhoot DS. Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Am J Ophthalmol. 2025. PMID: 40505850. doi:10.1016/j.ajo.2025.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。